Literature DB >> 31366713

Prostaglandin E2-Induced Immune Exhaustion and Enhancement of Antiviral Effects by Anti-PD-L1 Antibody Combined with COX-2 Inhibitor in Bovine Leukemia Virus Infection.

Yamato Sajiki1, Satoru Konnai2,3, Tomohiro Okagawa3, Asami Nishimori1, Naoya Maekawa3, Shinya Goto1, Kei Watari1, Erina Minato4, Atsushi Kobayashi4, Junko Kohara5, Shinji Yamada6, Mika K Kaneko6, Yukinari Kato6, Hirofumi Takahashi7, Nobuhiro Terasaki7, Akira Takeda7, Keiichi Yamamoto3,8, Mikihiro Toda3,9, Yasuhiko Suzuki3,10,11, Shiro Murata1,3, Kazuhiko Ohashi1,3.   

Abstract

Bovine leukemia virus (BLV) infection is a chronic viral infection of cattle and endemic in many countries, including Japan. Our previous study demonstrated that PGE2, a product of cyclooxygenase (COX) 2, suppresses Th1 responses in cattle and contributes to the progression of Johne disease, a chronic bacterial infection in cattle. However, little information is available on the association of PGE2 with chronic viral infection. Thus, we analyzed the changes in plasma PGE2 concentration during BLV infection and its effects on proviral load, viral gene transcription, Th1 responses, and disease progression. Both COX2 expression by PBMCs and plasma PGE2 concentration were higher in the infected cattle compared with uninfected cattle, and plasma PGE2 concentration was positively correlated with the proviral load. BLV Ag exposure also directly enhanced PGE2 production by PBMCs. Transcription of BLV genes was activated via PGE2 receptors EP2 and EP4, further suggesting that PGE2 contributes to disease progression. In contrast, inhibition of PGE2 production using a COX-2 inhibitor activated BLV-specific Th1 responses in vitro, as evidenced by enhanced T cell proliferation and Th1 cytokine production, and reduced BLV proviral load in vivo. Combined treatment with the COX-2 inhibitor meloxicam and anti-programmed death-ligand 1 Ab significantly reduced the BLV proviral load, suggesting a potential as a novel control method against BLV infection. Further studies using a larger number of animals are required to support the efficacy of this treatment for clinical application.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Year:  2019        PMID: 31366713      PMCID: PMC6697740          DOI: 10.4049/jimmunol.1900342

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  58 in total

1.  Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus.

Authors:  D Pyeon; F J Diaz; G A Splitter
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 2.  Distinct functions of COX-1 and COX-2.

Authors:  Ikuo Morita
Journal:  Prostaglandins Other Lipid Mediat       Date:  2002-08       Impact factor: 3.072

3.  Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors.

Authors:  D Derse; S A Hill; P A Lloyd; B A Morse
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 4.  Host immune responses in the course of bovine leukemia virus infection.

Authors:  H Kabeya; K Ohashi; M Onuma
Journal:  J Vet Med Sci       Date:  2001-07       Impact factor: 1.267

Review 5.  Prostaglandins as modulators of immunity.

Authors:  Sarah G Harris; Josue Padilla; Laura Koumas; Denise Ray; Richard P Phipps
Journal:  Trends Immunol       Date:  2002-03       Impact factor: 16.687

6.  Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton.

Authors:  Tadahiko Igakura; Jane C Stinchcombe; Peter K C Goon; Graham P Taylor; Jonathan N Weber; Gillian M Griffiths; Yuetsu Tanaka; Mitsuhiro Osame; Charles R M Bangham
Journal:  Science       Date:  2003-02-13       Impact factor: 47.728

7.  Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis.

Authors:  M Stolina; S Sharma; Y Lin; M Dohadwala; B Gardner; J Luo; L Zhu; M Kronenberg; P W Miller; J Portanova; J C Lee; S M Dubinett
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

8.  Seroprevalence of antibodies against bovine leukemia virus, bovine viral diarrhea virus, Mycobacterium avium subspecies paratuberculosis, and Neospora caninum in dairy cattle in Saskatchewan.

Authors:  John A VanLeeuwen; LeeAnn Forsythe; Ashwani Tiwari; Renee Chartier
Journal:  Can Vet J       Date:  2005-01       Impact factor: 1.008

Review 9.  A new view of prostaglandin E regulation of the immune response.

Authors:  R P Phipps; S H Stein; R L Roper
Journal:  Immunol Today       Date:  1991-10

10.  A cyclic AMP-responsive DNA-binding protein (CREB2) is a cellular transactivator of the bovine leukemia virus long terminal repeat.

Authors:  L Willems; R Kettmann; G Chen; D Portetelle; A Burny; D Derse
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

View more
  16 in total

1.  Prostaglandin E2-Induced Immune Suppression via Cytotoxic T-Lymphocyte Antigen 4 in Paratuberculosis.

Authors:  Yamato Sajiki; Satoru Konnai; Kei Watari; Tomohiro Okagawa; Akina Tanaka; Satoko Kawaji; Reiko Nagata; Naoya Maekawa; Yasuhiko Suzuki; Yukinari Kato; Shiro Murata; Yasuyuki Mori; Kazuhiko Ohashi
Journal:  Infect Immun       Date:  2022-09-14       Impact factor: 3.609

Review 2.  Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19.

Authors:  Calum T Robb; Marie Goepp; Adriano G Rossi; Chengcan Yao
Journal:  Br J Pharmacol       Date:  2020-08-27       Impact factor: 8.739

Review 3.  The Effect of Lipid Metabolism on CD4+ T Cells.

Authors:  Feiyang Cai; Shuxin Jin; Guangjie Chen
Journal:  Mediators Inflamm       Date:  2021-01-05       Impact factor: 4.711

4.  Tick saliva-induced programmed death-1 and PD-ligand 1 and its related host immunosuppression.

Authors:  Yamato Sajiki; Satoru Konnai; Yoshinori Ikenaka; Kevin Christian Montecillo Gulay; Atsushi Kobayashi; Luís Fernando Parizi; Benvindo Capela João; Kei Watari; Sotaro Fujisawa; Tomohiro Okagawa; Naoya Maekawa; Carlos Logullo; Itabajara da Silva Vaz; Shiro Murata; Kazuhiko Ohashi
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

Review 5.  Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy.

Authors:  Xiangyu Deng; Zengwu Shao; Yanli Zhao
Journal:  Adv Sci (Weinh)       Date:  2021-01-05       Impact factor: 16.806

6.  The Suppression of Th1 Response by Inducing TGF-β1 From Regulatory T Cells in Bovine Mycoplasmosis.

Authors:  Yamato Sajiki; Satoru Konnai; Shinya Goto; Tomohiro Okagawa; Kosuke Ohira; Honami Shimakura; Naoya Maekawa; Satoshi Gondaira; Hidetoshi Higuchi; Motoshi Tajima; Yuki Hirano; Junko Kohara; Shiro Murata; Kazuhiko Ohashi
Journal:  Front Vet Sci       Date:  2020-12-02

7.  The enhancement of Th1 immune response by anti-PD-L1 antibody in cattle infected with Mycobacterium avium subsp. paratuberculosis.

Authors:  Yamato Sajiki; Satoru Konnai; Reiko Nagata; Satoko Kawaji; Hayato Nakamura; Sotaro Fujisawa; Tomohiro Okagawa; Naoya Maekawa; Yukinari Kato; Yasuhiko Suzuki; Shiro Murata; Yasuyuki Mori; Kazuhiko Ohashi
Journal:  J Vet Med Sci       Date:  2020-12-07       Impact factor: 1.267

8.  Upregulation of PD-L1 Expression by Prostaglandin E2 and the Enhancement of IFN-γ by Anti-PD-L1 Antibody Combined With a COX-2 Inhibitor in Mycoplasma bovis Infection.

Authors:  Shinya Goto; Satoru Konnai; Yuki Hirano; Junko Kohara; Tomohiro Okagawa; Naoya Maekawa; Yamato Sajiki; Kei Watari; Erina Minato; Atsuhi Kobayashi; Satoshi Gondaira; Hidetoshi Higuchi; Masateru Koiwa; Motoshi Tajima; Eiji Taguchi; Ryoko Uemura; Shinji Yamada; Mika K Kaneko; Yukinari Kato; Keiichi Yamamoto; Mikihiro Toda; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Journal:  Front Vet Sci       Date:  2020-02-20

9.  PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.

Authors:  Otgontuya Ganbaatar; Satoru Konnai; Tomohiro Okagawa; Yutaro Nojima; Naoya Maekawa; Erina Minato; Atsushi Kobayashi; Ryo Ando; Nobuya Sasaki; Daisuke Miyakoshi; Osamu Ichii; Yukinari Kato; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Journal:  PLoS One       Date:  2020-11-20       Impact factor: 3.240

10.  2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1.

Authors:  Zhanfei Chen; Yiyin Chen; Lirong Peng; Xiaoqian Wang; Nanhong Tang
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.